Je selectiemandje is leeg.
Maak een selectie van ETF's die je wilt vergelijken.
Voeg een ETF toe door op "Vergelijk" te klikken op een ETF-profiel of door een ETF aan te vinken in de ETF-zoekfunctie.
Alnylam Pharmaceuticals
ISIN US02043Q1076
|WKN A0CBCK
Marktkapitalisatie (in EUR)
36,701 m
Land
United States
Sector
Healthcare
Dividendrendement
0.00%
Overzicht
Koers
Beschrijving
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Grafiek
Financiële kerngegevens
Kerncijfers
| Marktkapitalisatie, EUR | 36,701 m |
| WPA, EUR | 2.00 |
| KBV | 53.8 |
| K/W | 137.6 |
| Dividendrendement | 0.00% |
Income statement (2025)
| Omzet, EUR | 3,292 m |
| Netto-inkomen, EUR | 278 m |
| Winstmarge | 8.45% |
What ETF is Alnylam Pharmaceuticals in?
There are 45 ETFs which contain Alnylam Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Alnylam Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Prestaties
Rendementsoverzicht
| YTD | -18,61% |
| 1 maand | -0,47% |
| 3 maanden | -29,80% |
| 6 maanden | -28,36% |
| 1 jaar | +20,06% |
| 3 jaar | +47,49% |
| 5 jaar | +131,02% |
| Since inception | +152,05% |
| 2025 | +50,24% |
| 2024 | +27,70% |
| 2023 | -20,53% |
| 2022 | +48,60% |
Maandelijks rendement in een heat map
Risico
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risico-overzicht
| Volatiliteit 1 jaar | 43,10% |
| Volatiliteit 3 jaar | 42,40% |
| Volatiliteit 5 jaar | 46,90% |
| Rendement/Risico 1 jaar | 0,47 |
| Rendement/Risico 3 jaar | 0,33 |
| Rendement/Risico 5 jaar | 0,39 |
| Maximaal waardedaling 1 jaar | -38,48% |
| Maximaal waardedaling 3 jaar | -38,48% |
| Maximaal waardedaling 5 jaar | -41,13% |
| Maximaal waardedaling sinds aanvang | -41,13% |
Voortschrijdende volatiliteit over 1 jaar
Nieuwste artikelen
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.